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Abstract Epidermolysis bullosa simplex (EBS) is a heredi-
tary genodermatosis characterised by trauma-induced
intraepidermal blistering of the skin. EBS is mostly caused
by mutations in the KRT5 and KRT14 genes. Disease severity
partially depends on the affected keratin type and may be
modulated by mutation type and location. The aim of our
study was to identify the molecular defects in KRT5 and
KRT14 in a cohort of 46 Polish and one Belarusian probands
with clinical suspicion of EBS and to determine the genotype–
phenotype correlation. The group of 47 patients with clinical
recognition of EBS was enrolled in the study. We analysed all
coding exons of KRT5 and KRT14 using Sanger sequencing.
The pathogenic status of novel variants was evaluated using
bioinformatical tools, control group analysis (DNA from 100
healthy population-matched subjects) and probands’ parents
testing. We identified mutations in 80 % of patients and found
29 different mutations, 11 of which were novel and six were
found in more than one family. All novel mutations were
ascertained as pathogenic. In the majority of cases, the most
severe genotype was associated with mutations in highly con-
served regions. In some cases, different inheritance mode and
clinical significance, than previously reported by others, was
observed. We report 11 novel variants and show novel geno-
type–phenotype correlations. Our data give further insight into
the natural history of EBSmolecular pathology, epidemiology
and mutation origin.
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Introduction
Epidermolysis bullosa simplex (EBS) is a rare hereditary
genodermatosis characterised by intraepidermal blistering of
the skin upon mild trauma (Fine 2010). Several subtypes of
EBS have been described according to clinical, ultrastructural
and molecular findings. The most frequent variants are: EBS,
localised (EBS-loc) with blistering confined to the hands and
feet, EBS-generalised intermediate (EBS-gen intermed, for-
merly non-Dowling-Meara or EBS-gen nDM), in which blis-
tering occurs on the whole body area, and more severe: EBS-
generalised severe (EBS-gen sev, formerly Dowling-Meara or
EBS-gen DM), where mucosa is also involved (Coulombe
and Lee 2012; Fine et al. 2008). In more than 75 % of cases,
EBS is caused by mutations in the KRT5 and KRT14 genes,
affecting keratin 5 (K5) or keratin 14 (K14), respectively
(Bolling et al. 2011); however, mutations in nine other genes
were reported to cause the EBS phenotype (Fine et al. 2014).
EBS can be inherited in autosomal dominant or recessive
mode. More than 86 % of mutations occurring in KRT5 or
KRT14 are dominantly acting missenses (Coulombe and Lee
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2012; Fine et al. 2008). Regardless of the keratin type affected,
most of these mutations change amino acid residues in the
central L-helical rod domain, leading to more severe EBS
phenotypes. In contrast, milder EBS is often caused by muta-
tions in the K5 located in non-helical linker regions and in the
head domain (Coulombe and Lee 2012). In addition, the se-
verity of the disease is further modulated by the location of
substituted amino acid within repetitive motif [i.e. heptad
structure (abcdefg)n] of the helical domain. According to the
superhelix model, the phenotype caused by substitutions of
amino acids directly involved in the interaction between het-
erodimeric keratins is more severe compared to those affecting
other residues (Pauling and Corey 1953; Müller et al. 2006).
Furthermore, other data indicate that mutation dosage and
biophysical properties of introduced amino acids are also of
importance with regards to exacerbation of the EBS severity
(Shinkuma et al. 2013; Ołdak et al. 2011).
Objective
The aim of our study was to identify the molecular defects in
the KRT5 and KRT14 genes in a cohort of 46 Polish and one
Belarusian probands with clinical suspicion of EBS and to
determine the genotype–phenotype correlations.
Materials and methods
Study subjects
The cohort of 47 EBS probands from 47 families and their
family members were enrolled in the study. EBS was diag-
nosed based on clinical symptoms (according to the consensus
from 2014; Fine et al. 2014) and/or of skin biopsies results.
DNA isolated from 100 healthy population-matched subjects
was used as control samples.
All participants gave formal consent for their participation
in the study. The study was approved by the local ethics
committee.
Mutation analysis
The mutation analysis of KRT5 and/or KRT14 was performed
using Sanger sequencing. Primers for KRT14 were as de-
scribed previously (Ołdak et al. 2010) and for KRT5 self-
des igned in PRIMER3 (ava i l ab l e on reque s t ) .
Fluorochromatograms were analysed in Mutation Surveyor
software using NM_000526 and NM_000424 as references
for KTR14 and KRT5, respectively. The control group was
screened for each of the novel mutations identified by us.
The mutation segregation in the family was performed for
27 out of 38 families. For the remaining patients, the DNA
from their parents and/or other relatives was not available.
In silico analysis
The Clustal X analysis was performed to check evolutionary
conservation of novel mutations, the SSF (Splicing Sequences
Finder), NNSPLICE (Splice Site Prediction by Neural
Network) and HSF (Human Splicing Finder) softwares were
used to evaluate in silico the potential effect of novel variants




In 38/47 probands, we detected mutations in either KRT5 or
KRT14 and, in one case, we found mutations in both genes. In
total, we identified 29 different mutations, i.e. 16 inKRT5 and
13 in KRT14, 11 of them were novel and six were recurrent
(KRT5: p.Glu170Lys, p.Leu325Phe, p.Val186Met; KRT14:
p.Arg125His, p.Met272Thr, p.Val133Met). Genotyping re-
sults, mutations details and the family segregation results are
given in Table 1.
In silico characteristics of novel mutations
Alignment of epidermal keratins type I and II showed that
novel missenses and in frame deletion localise in highly con-
served regions of K5 or K14 proteins. All missenses were
assigned as ‘probably pathogenic’ by the PolyPhen-2 algo-
rithm. Total abolition of the intron 1 acceptor site in KRT5
by c.556-2A>Gwas indicated unanimously, which, according
to in silico predictions, leads to aberrant pre-mRNA splicing
and production of a truncated protein. No mutations in KRT5
and KRT14 were found in the control group.
Discussion
Although EBS has heterogenic genetic background, KRT5
and KRT14 are the most important genes in the development
of this disorder and EBS can still be regarded as a model
keratinopathy.
We identified mutations in KRT5 or/and KRT14 genes in
38 unrelated patients; that is, on one of the largest published
groups of patients (Bolling et al. 2011; Jerábková et al. 2010;
Chen et al. 1995; Pfendner et al. 2005; Arin et al. 2010).
Although around 120 mutations in KRT5 and 95 in KRT14
genes were published so far and patients of Central European
origin were also included in other reports, we not only identi-
fied recurrent mutations but were also able to find unique and
novel ones.
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Table 1 Results of the molecular analysis of Polish patients with epidermolysis bullosa simplex (EBS)
Number Gene EBS subtype Genotype traditional Genotype HGVS Exon Domain Heptad Inheritance
1 KRT14 EBS-gen sev p.Tyr129Asp/- c.[385T>G];[=] 1 1a d de novo
2 KRT14 EBS-gen intermed p.Val133Met/- c.[397G>A];[=] 1 1a a AD
3 KRT14 EBS-gen sev p.Met119Thr/- c.[356T>C];[=] 1 1a a n.d.
4 KRT14 n.d. p.Glu411del/- c.[1231_1233delGAG];[=] 6 2b g n.d.
5 KRT14 n.d. p.Arg388Cys/- c.[1162C>T];[=]. 7 2b e AD
6 KRT14 n.d. p.Arg125His/- c.[374G>A];[=] 1 1a g AD
7 KRT14 EBS-gen sev p.Arg125His/- c.[374G>A];[=] 1 1a g AD
8 KRT14 EBS-loc p.Val133Met/- c.[397G>A];[=] 1 1a a AD
9 KRT14 EBS-gen sev p.Arg125Cys/- c.[373C>T];[=] 1 1a g de novo
10 KRT14 n.d. p.Arg125Leu/-a c.[374G>T];[=] 1 1a g de novo (?)
11 KRT14 EBS-loc p.Val270Ala/-b c.[809T>C];[=] 4 l12 n.a. de novo
12 KRT14 EBS-loc p.Ala413Thr/- c.[1237G>A];[=] 6 2b b n.d.
13 KRT14 EBS-loc p.Val133Met/- c.[397G>A];[=] 1 1a a n.d.
14* KRT14 EBS-gen sev p.Asn123Ser/- c.[368A>G];[=] 1 1a e de novo
15 KRT14 EBS-loc p.Met272Thr/- c.[815T>C];[=] 4 l12 n.a. AD




7 4 2b l12 e n.a. AD
17 KRT14 EBS-loc/gen p.Leu418Gln/-d c.[1253T>A];[=] 6 2b g AD
18 KRT14 n.d. p.Met272Thr/- c.[815T>C];[=] 4 l12 n.a. AD
19 KRT5 n.d. p.Leu203Met/- c.[607C>A];[=] 2 1a d AD
20 KRT5 EBS-gen intermed p.Val186Met/- c.[556G>A];[=] 2 1a a AD
21 KRT5 EBS-gen intermed p.Val186Met/- c.[556G>A];[=] 2 1a a AD
22 KRT5 EBS-loc p.Glu170Lys/- c.[508G>A];[=] 1 1a f AD (partial
penetration)
23 KRT5 EBS-loc p.Leu325Phe/- c.[973C>T];[=] 2 l12 n.a. AD
24 KRT5 EBS-gen sev p.Thr144_Val145del/- c.[431_436delCTGTCA];[=] 1 head n.a. de novo
25 KRT5 EBS-loc p.Asn146Tyr/- c.[436A>T];[=] 1 head n.a. AD
26 KRT5 n.d. c.556-2A>G/- c.[556-2G>A];[=] 2 1a n.a. AD
27 KRT5 EBS-loc p.Glu170Lys/- c.[508G>A];[=] 1 1a f (?)
28 KRT5 EBS-gen intermed p.Val143Ala/Glu170Lys c.[428T>C];[508G>A] 1 head/1a f AR
29 KRT5 n.d. p.Leu325Phe/- c.[973C>T];[=] 5 l12 n.a. AD
30 KRT5 EBS-gen intermed p.Glu170Lys/Glu170Lyse c.[508G>A];[508G>A] 1 1a f AD (partial
penetration)
31 KRT5 n.d. p.Glu190Lys/- c.[568G>A];[=] 2 1a e AD
32 KRT5 n.d. p.Val143Phe/- c.[427G>T];[=] 1 head n.a. de novo (?)
33 KRT5 n.d. p.Glu477Gly/-f c.[1430A>G];[=] 7 2b d n.d.
34 KRT5 EBS-loc (!!) p.Gly476Asp/-g c.[1427G>A];[=] 7 2b c AD
35 KRT5 EBS-MP p.Pro25Leu/-f c.[74C>T];[=] 1 head n.a. n.d.
36 KRT5 EBS-loc p.Leu325Pro/-f c.[974T>C];[=] 2 l12 n.a. n.d.
37 KRT5 EBS-loc p.Glu170Lys/- c.[508G>A];[=] 1 1a f n.d.
38 KRT5 n.d. p.Tyr470Ter/- c.[1410C>G];[=] 7 2b d de novo
39–47 KRT5, KRT14 n.d. -/- c.[=];[=] n.a. n.a. n.a. n.d.
(!) EBS-loc in heterozygous members of the family (genotyped as p.Met272Thr/-); (!!) EBS-gen intermed seen in one family member; n.a. not
applicable; n.d. no data; AD autosomal dominant; AR autosomal recessive; (?) de novo event is suggested based on family history, but no molecular
confirmation has been performed. Novel mutations are in bold
*Patient of Belarusian origin
The letters in superscript refer to the following references with profound description of our case: a Ołdak et al. (2010); b Ołdak et al. (2013); c Wertheim-
Tysarowska et al. (2014); d Jankowski et al. (2014); e Ołdak et al. (2011); f Hamada et al. (2005); g Kowalewski et al. (2009)
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All recurrent mutations from our group, except for
p.Leu325Phe in KRT5, were previously described (Table 2). In
contrast to the widely known hot spot of KRT14 codon 125, in
which six different amino acid substitutions were described in
over 67 patients worldwide, the origin of the other mutations is
less clear (Human Intermediate Filament Database; Szeverenyi
et al. 2008; Rugg et al. 2007). According to published data, the
p.Glu170Lys in KRT5 and p.Met272Thr in KRT14 were mostly
found in patients originating from Central Europe, which may
strongly suggest common ancestry. The p.Val133Met was re-
ported previously in two Scottish families (Rugg et al. 2007).
The data about these families are highly limited, but due to
centuries of close relations between Poland and Scotland, we
cannot rule out that, in this case, common origin is a clue once
again. However, the fact that two other amino acid substitutions
of Val 133 are known, of which the p.Val133Leu is seemingly
more common in Europe, we cannot rule out that codon 133 is
prone to mutational events. Finally, the p.Val186Met, which was
found in distinct populations (Turkey, Japan and Poland) and
also represents only one out of three different valine 186 amino
acid substitutions, seems to be the probable mutational hot spot
(Arin et al. 2010; Hattori et al. 2006; Yasukawa et al. 2006).
We also identified two families with p.Leu325Phe in
KRT5. We cannot speculate about the origin of this mutation,
since we were unable to test whether both families share
ancestry. Noteworthy, another mutation of codon 325
(p.Leu325Pro) has also been found and, therefore, we cannot
excluded that this codon is another one which is prone to
mutational events and these mutations arose independently
(Sørensen et al. 1999; Hamada et al. 2005).
The correlation between phenotype and genotype can only
be performed when the EBS subtype is recognised on the
basis of clinical symptoms, which tend to change over time.
Therefore, in some patients, it is not possible to make a proper
diagnosis during early childhood. This explains mostly the
reason why, in some probands, we could not determine the
EBS subtype. However, the other important issue was that
some of them had dermatological consultation once or twice
only, making proper subtype distinction highly tentative.
It is generally accepted that mutations inKRT5 are, overall,
associated with milder clinical outcome and that the location
of mutation within the most conserved regions of K5 and K14
is linked to a more severe clinical picture. We also observe
such tendencies in our heterozygous patients. Most of our
Table 2 Summary of patients with selected recurrent mutations in KRT5 and KRT14 genes identified by us and others





KRT5 c.[508G>A];[=] p.[Glu170Lys];[=] Germany 1 F Müller et al. (2006)
Hungary 1 F Glász-Bóna et al. (2009)
Czech Republic 1 F Jerábková et al. (2010)
China 1 F Tang et al. (2009)
Japan 1 F Yasukawa et al. (2006)
Poland 1 F This work
Poland 2 unknown
c.[428T>C];[508G>A] p.[Val143Ala];[Glu170Lys] Poland 1 F
c.[508G>A];[508G>A] p.[Glu170Lys];[Glu170Lys] Poland 1 F
Total 10
c.[556G>A];[=] p.[Val186Met];[=] Turkey 1 F Arin et al. (2010)
Japan 1 de novo Hattori et al. (2006)
Japan 1 F Yasukawa et al. (2006)
Poland 2 F This work
Total 5
KRT14 c.[815T>C];[=] p.[Met272Thr];[=] Germany 4 F Arin et al. (2010)
Germany 1 de novo Müller et al. (2006)
Poland 3 F This work
Total 8
c.[397G>A];[=] p.[Val133Met];[=] Scotland 2 F Rugg et al. (2007)
Poland 2 F This work
Poland 1 unknown
Total 5
Recurrent mutations are bolded
F familial
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mutations (16 vs. 13) were located in the KRT5 gene, which is
in accordance with the fact that patients were predominantly
EBS-loc. Furthermore, 90 % (8/9) of mutations identified in
patients with generalised EBS subtypes (severe and interme-
diate) are localised in helical segment 1a or 2b of either K5 or
K14, while far fewer, 50 % (6/12), of mutations found in
localised EBS patients share this location. Furthermore, our
results are also in agreement with the model of Liovic et al.
(2001): the precise location of a given amino acid within
heptad repetitive sequence (abcdefg)n modulates further the
disease severity. Amino acids at positions a/d and e/g are direct-
ly involved in maintenance and stabilisation of the K5/K14
heterodimer; thus, their substitutions are more deleterious
(Smith et al. 2004; Müller et al. 2006). Indeed, 8/8 (100 %) of
mutations localised in the 1a segment in patientswith generalised
EBS subtypes are situated in these positions. On the contrary,
only 33 % (2/6) of mutations found in 1a or 2b segments in
EBS-loc patients were identified in position ‘a.’ These obser-
vations are highly encouraging with respect to phenotype pre-
diction purposes; however, a closer look reveals a possible
engagement of other modulatory factors (e.g. sequence varia-
tions in other alleles or genes encoding other keratins).
The most frequent mutation, p.Glu170Lys in KRT5,
according to our findings and data published by others
can have various clinical consequences (Ołdak et al.
2010; Müller et al. 2006; Jerábková et al. 2010; Arin
et al. 2010; Yasukawa et al. 2002). This substitution oc-
curred in five probands of our group. In three EBS-loc
patients, it was present in one allele and no other muta-
tions in KRT5 or KRT14 were detected. However, in two
remaining pat ients with EBS-gen intermed, the
p.Glu170Lys was found in both alleles or in a heterozy-
gous state with p.Val143Ala. The first case has already
been reported by Ołdak et al. (2011), who found symp-
t oms o f l o c a l i s ed EBS in bo t h he t e r o zygous
(p.Glu170Lys/-) parents of the patient. Interestingly, in
the proband’s older sister, despite the same genotype
(p.Glu170Lys/-), no clinical symptoms were observed
(Fig. 1). In the second family, the proband and her EBS-
gen intermed brother were both genotyped as compound
heterozygotes p.Glu170Lys/p.Val143Ala (Fig. 1). Both
parents were proved to be carriers of p.Glu170Lys
(father) or p.Val143Ala (mother), and none of them re-
ported any cl inical s igns of EBS. Of note, the
p.Val143Ala mutation was previously described in the lit-
erature, in two patients with autosomal dominant EBS-loc
(Jerábková et al. 2010). Why some p.Glu170Lys and
p.Val143Ala heterozygotes do have clinical symptoms of
EBS-loc and others do not remains an open question.
According to our knowledge, there is only one another
patient, reported by Yasukawa et al. (2002), with the
p.Glu170Lys mutation in compound heterozygosity with
the other mutation (p.Glu418Lys) in KRT5. In this case,
clinical symptoms and also keratin clumping during
in vitro assay were aggravated when both mutations were
present. However, in this case, the p.Glu170Lys without
p.Glu418Lys was identified in family members with
milder disease. Furthermore, we found EBS-loc and
EBS-gen intermed ratio 1:1 in one large family with




Fig. 1 Pedigrees of families 16 (a), 28 (b) and 30 (c) showing probands
and their first-degree relatives. Symbols: half-black heterozygous
mutation inKRT5; solid blackmutation in both alleles ofKRT5; half-grey
heterozygous mutation in KRT14; checkered pattern mutation in one
allele of KRT5 and in one allele of KRT14; = no mutation detected in
single allele; * feet skin fragility, but the final diagnosis of epidermolysis
bullosa (EB) and EB type/subtype has not been confirmed clinically (a:
modified fromWertheim-Tysarowska et al. 2014; c: modified fromOłdak
et al. 2011)
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digenic KRT5 and KRT14 EBS (Fig. 1; Wertheim-
Tysarowska et al. 2014; Jankowski et al. 2014).
Another example is p.Leu325Phe in KRT5, where we have
also encountered some difficulties in establishing its pathogenic
status and phenotypic effect. It was identified in the EBS-loc
patient, her affected father and grandfather. The grandfather
claimed to be healthy, but admitted his mother (the proband’s
great grandmother, deceased, not analysed) had clinical symp-
toms resembling EBS. Since the grandfather did not agree for
clinical evaluation, we only had limited data available, but
managed to establish that slight skin changes (e.g. keratoder-
ma) were present. Furthermore, we also detected the
p.Leu325Phe in the other EBS-loc family, where, in contrast,
we were able to show its cosegregation with the EBS pheno-
type (six affected patients) and prove its pathogenic status.
Overall, our observations regarding genotype–phenotype
correlations have important impact on genetic counselling,
indicating that offspring phenotype can vary from parental
clinical outcome and that full sequencing of both keratins
should be considered in the case of the EBS patient’s partner.
In about 17 % of our probands, particularly in generalised
EBS cases, mutations were due to de novo events (or resulted
from a germinal mosaicism). This number is lower than that
reported by others (Bolling et al. 2011; Jerábková et al. 2010;
Pfendner et al. 2005), but still indicates the high rate of spon-
taneous events. Nevertheless, we have also shown that parent
testing is indispensable in order to exclude the possibility of
being an asymptomatic carrier or having discrete EBS pheno-
type. Therefore, we also suggest to perform analysis of the
whole coding region of KRT5 and KRT14 in patients whose
phenotype is more severe than that observed in other family
members.
Although EBS is the most frequent type of EB, recent
findings prove that there are still a lot of unanswered questions
regarding natural history of the disease and its genetic back-
ground (Hamada et al. 2013). Molecular analyses performed
worldwide indicate that KRT5 and KRT14 mutations are re-
sponsible for the majority of EBS and can be found in 70–
75 % of patients (Bolling et al. 2011; Rugg et al. 2007). Thus,
the detection rate observed by us in this study (80 %) is in
agreement with the results obtained by others.
It should be noted however, that another skin disorder, acral
peeling skin syndrome (APSS, caused by mutations in
TGM5), has only recently been classified as another subtype
of EBS (Fine et al. 2014). Therefore, when all Polish probands
with APSS (n=20; for further details, see Szczecinska et al.
2014) and other types of EBS (n=47; this study) are consid-
ered (n=20+47=67), the numbers change as follows: KRT5
andKRT14mutations are present in 38/67 (57%) of total EBS
probands and mutations in TGM5 in 20/67 (30 %) probands.
Hence, analysis of these three genes gives a total detection rate
of 87 % in the Polish population of EBS patients classified
according to current recommendations.
The lack of mutations in KRT5 and KRT14 in nine patients
(who were also negative for TGM5 mutations, data not
shown) may indicate an existence of large rearrangements or
mutations either in intronic/regulatory elements of KRT14,
KRT5 and TGM5 or, more likely, in the other genes. Indeed,
EBS is the most heterogenic type of EB and has recently been
proved to be caused by mutations in at least eight other genes
besides KRT5, KRT14 and TGM5, which are: PLEC, PKP1,
DSP, JUP,DST, EXPH5, ITGA6 and ITGB4 (Fine et al. 2014).
Extended molecular analyses are planned in the future.
In summary, our data provide further insight into EBS mo-
lecular pathology, natural history and epidemiology: we pro-
vide novel evidence that more mutations than we thought
earlier can have variable clinical significance and give more
data concerning the origin of several mutations. Our results
are of particular importance for genetic counselling and prog-
nostic purposes, and have practical implication in diagnostics.
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